Literature DB >> 32615390

Fecal transplants as a microbiome-based therapeutic.

Nadeem O Kaakoush1.   

Abstract

Impaired microbiome diversity and composition can develop into a potent etiological agent of disease and increase susceptibility to infection. Given this, interventions targeting the microbiome have developed rapidly, with healthy donor feces being a de facto source of beneficial communities employed to rebalance patients' microbiomes. Recent evidence has demonstrated that bacterial and viral richness, short chain fatty acid production, bile acid conversion as well as presence of bacterial and fungal pathobionts are associated with therapy efficacy; however, little is known of the influence of host factors such as genetics, medications, and diet. Here, current knowledge on factors associated with fecal transplant efficacy, as well as efforts to transition to other forms of therapy are reviewed.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32615390     DOI: 10.1016/j.mib.2020.05.008

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  2 in total

1.  Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules.

Authors:  Qingqing Guo; Hao Lin; Pengcheng Chen; Songlin Tan; Zhiyong Wen; Lijian Lin; Jianquan He; Jianbo Wen; Shiyun Lu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  L2Δ13, a splicing isoform of lysyl oxidase-like 2, causes adipose tissue loss via the gut microbiota and lipid metabolism.

Authors:  Yang Chen; Li-Xia He; Jin-Ling Chen; Xin Xu; Juan-Juan Wang; Xiu-Hui Zhan; Ji-Wei Jiao; Geng Dong; En-Min Li; Li-Yan Xu
Journal:  iScience       Date:  2022-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.